Minerals Technologies Inc. — 2023 Form 10-K
Business context and reporting period. This is an annual report for the fiscal year ended December 31, 2023, not a standalone fourth-quarter report. Minerals Technologies develops and sells specialty mineral products, systems and services worldwide. Effective January 1, 2023, it reorganized into Consumer & Specialties and Engineered Solutions.
Financial performance
| Metric | 2023 | 2022 |
|---|---|---|
| Net sales | $2,169.9 million | $2,125.5 million |
| Production margin | $507.1 million; 23.4% | $465.0 million; 21.9% |
| Income from operations | $171.8 million; 7.9% margin | $214.8 million; 10.1% margin |
| Net income attributable to MTI | $84.1 million; diluted EPS $2.58 | $122.2 million; diluted EPS $3.73 |
| Cash provided by operating activities | $233.6 million | $105.7 million |
| Capital expenditures | $93.5 million | $82.3 million |
- Consumer & Specialties sales rose 3.2% to $1,160.2 million; segment operating income was $41.6 million. Household & Personal Care sales grew 8.7%, while Specialty Additives sales declined 0.9%.
- Engineered Solutions sales rose 0.9% to $1,009.7 million; segment operating income was $147.8 million. High-Temperature Technologies sales grew 2.6%; Environmental & Infrastructure sales fell 3.2%, reflecting weak commercial construction.
- Cash and short-term investments totaled $321.5 million at year-end. Management reported more than $500 million of available liquidity, including cash and revolving-facility availability. Current assets were $1,099.0 million and current liabilities $457.3 million.
- Aggregate debt principal was $1,020.8 million at year-end, primarily $532.8 million under the term facility, $400 million of 5.0% notes due 2028, and $85 million drawn on the revolving facility. A further $205.6 million was available under the revolver after outstanding letters of credit. Net interest expense increased to $59.2 million from $43.9 million, primarily due to higher rates.
Material changes and unusual items
- Sales increased 2.1%, but MTI-attributable net income fell 31.2% and diluted EPS declined from $3.73 to $2.58. Operating income decreased 20.0%; higher production margin did not offset special charges and increased operating expenses.
- 2023 included a $71.7 million non-cash impairment of Barretts’ fixed assets, $29.2 million of net talc-related litigation expenses, and $6.9 million of restructuring charges. Management reported an $85.8 million after-tax charge from impairment, litigation, restructuring and acquisition-related costs.
- On October 2, 2023, Barretts subsidiaries filed for Chapter 11 protection to address talc liabilities. They were deconsolidated from MTI’s financial statements following the filing; MTI and its other subsidiaries were not included in the bankruptcy filing.
- The reporting-segment realignment affects comparisons with prior-year segment results. Barretts’ fourth-quarter 2022 sales were $12.0 million, while it was deconsolidated in 2023.
Outlook, risks and contingencies
- Management’s 2024 priorities include growth in pet litter and personal care, paper and packaging applications, refractory products, PFAS remediation, and environmental and infrastructure markets. No quantified revenue or earnings guidance is provided.
- Expected 2024 capital expenditures are $90–$100 million. Management plans to use cash flow for growth investment and debt reduction, with selective share repurchases.
- Management expects steel consumption and paper consumption in North America and Europe to be similar to 2023 levels. It cites weak commercial construction, cyclical end markets, inflation and energy costs, raw-material and freight volatility, foreign exchange, and international and geopolitical conditions as risks.
- At year-end, 574 talc-related cases were open. Claims against BMI were stayed in the Chapter 11 cases; certain claims against non-debtor affiliates were temporarily stayed through April 1, 2024, subject to extension. The ultimate resolution, timing and amount of talc liabilities cannot be estimated clearly. The filing notes possible exposure beyond accrued amounts and uncertainty over the scope of Pfizer’s indemnity.
- MTI reported compliance with its credit agreement covenants. The facility requires a maximum net leverage ratio of 4.00:1 and minimum interest coverage of 3.00:1. A one-percentage-point rate change was estimated to affect annual interest expense by $3.8 million.
Most important facts for investors to verify
- Progress and potential financial impact of the Barretts Chapter 11 cases, including any trust funding, affiliate exposure, and Pfizer indemnity outcome.
- Underlying earnings and segment margins excluding the impairment, litigation and restructuring charges, and the effect of Barretts’ deconsolidation on comparability.
- Debt reduction, interest costs, revolver availability, and covenant headroom as rates and operating conditions change.
- Whether the expected 2024 capital spending and stated growth initiatives translate into improved sales, margins and cash generation.